Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

2013100 citationsJournal Articlebronze Open Access

Authors

Howard A. Burris · Sarah Cannon

Fabienne Lebrun · Institut Jules Bordet

Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center

J. Thaddeus Beck · Highlands Oncology Group

Martine Piccart · Institut Jules Bordet

Patrick Neven · KU Leuven

José Baselga ·

Abstract

In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE.

Topics & Keywords

Cancer Treatment and Pharmacology Advanced Breast Cancer Therapies Cancer-related cognitive impairment studies

UN Sustainable Development Goals

Partnerships for the goalsGood health and well-being

Publication Details

Published in: Cancer

Volume 119, Issue 10, pp. 1908-1915

DOI: 10.1002/cncr.28010

Field-Weighted Citation Impact: 8.46

Command Palette